RPL19P5

Across TCGA pan-cancer cohorts, RPL19P5 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated RPL19P5 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL19P5 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL19P5 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUSC show a favorable association.

LUAD, LIHC, and BLCA are the cancer types where RPL19P5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.762	0.860	<.001	75	view →
LIHC	DFS	Tertile	All	0.333	0.515	<.001	63	view →
BLCA	DFS	Tertile	III,IV	0.766	0.317	<.001	57	view →
OV	OS	Tertile	II,III,IV	0.261	0.366	.002	52	view →
STAD	OS	Median	III,IV	0.218	0.512	.008	40	view →
UVM	OS	Median	III,IV	0.236	0.836	.002	26	view →
ACC	DFS	Tertile	All	0.348	0.648	.007	24	view →
LUSC	OS	Median	All	0.818	0.702	.002	23	view →
SARC	OS	Tertile	All	0.586	0.826	.001	21	view →
SKCM	OS	Median	III,IV	0.506	0.290	.006	14	view →
CESC	DFS	Tertile	II,III,IV	0.804	0.370	.009	12	view →
PRAD	OS	Median	All	1.000	0.988	.023	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

RPL19P5–LUAD (OS)

Open the LUAD breakdown →